Gilead (SYK Inhibitor Portfolio) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Gilead (SYK Inhibitor Portfolio) General Information

Description

A portfolio of two clinical-stage SYK inhibitors in Foster City, California.The inhibitors forming part of the acute myelogenous leukemia subset have been evaluated in oncology patients with autoimmune diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gilead (SYK Inhibitor Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gilead (SYK Inhibitor Portfolio)‘s full profile, request access.

Request a free trial

Gilead (SYK Inhibitor Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gilead (SYK Inhibitor Portfolio)‘s full profile, request access.

Request a free trial

Gilead (SYK Inhibitor Portfolio) FAQs

  • Where is Gilead (SYK Inhibitor Portfolio) headquartered?

    Gilead (SYK Inhibitor Portfolio) is headquartered in Foster City, CA.

  • What industry is Gilead (SYK Inhibitor Portfolio) in?

    Gilead (SYK Inhibitor Portfolio)’s primary industry is Buildings and Property.

  • Is Gilead (SYK Inhibitor Portfolio) a private or public company?

    Gilead (SYK Inhibitor Portfolio) is a Private company.

  • What is Gilead (SYK Inhibitor Portfolio)’s current revenue?

    The current revenue for Gilead (SYK Inhibitor Portfolio) is .

  • Who are Gilead (SYK Inhibitor Portfolio)’s investors?

    Gilead has invested in Gilead (SYK Inhibitor Portfolio).

  • When was Gilead (SYK Inhibitor Portfolio) acquired?

    Gilead (SYK Inhibitor Portfolio) was acquired on 16-Jul-2020.

  • Who acquired Gilead (SYK Inhibitor Portfolio)?

    Gilead (SYK Inhibitor Portfolio) was acquired by Kronos Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process